Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Trevi Therapeutics Inc (TRVI)
NASDAQ:TRVI
Holding TRVI?
Track your performance easily
TRVI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.97 - $4.00
Previous Close$3.51
Volume720.37K
Average Volume (3M)229.88K
Market Cap
$254.80M
Enterprise Value$186.50M
Total Cash (Recent Filing)$69.50M
Total Debt (Recent Filing)$1.19M
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Nov 07, 2024EPS Estimate
-$0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding72,591,917
10 Day Avg. Volume302,718
30 Day Avg. Volume229,881
Standard Deviation0.44
R-Squared0.01
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)3.51
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-6.12
Forecast
1Y Price Target
$9.11Price Target Upside159.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Trevi Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Phase IIa CANAL study of Haduvio in IPF chronic cough already demonstrated its potential as best-in-indication, reaching an encouraging, statistically significant treatment effect in cough frequency reduction.
Financial PerformanceTRVI ended 1Q24 with $72.8M of cash, cash equivalents, and marketable securities and reaffirmed sufficient cash runway into 2026.
Market OpportunitiesHaduvio’s potential in additional indications, including RCC, could drive long-term value for TRVI shares.
Bears Say
Market ReactionYear-to-date underperformance of -31% compared to -14% for XBI, largely attributed to chronic cough data catalyst vacuum.
Regulatory DelaysTRVI expects to request an end of Phase 2 (EOP2) meeting with the FDA in 2024, which is a delay from the previously expected 1Q24.
Stock PerformanceThe stock has underperformed year-to-date, with a -31% return compared to the broader biotech index's -14%.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
TRVI FAQ
What was Trevi Therapeutics Inc’s price range in the past 12 months?
Trevi Therapeutics Inc lowest stock price was $0.97 and its highest was $4.00 in the past 12 months.
What is Trevi Therapeutics Inc’s market cap?
Currently, no data Available
When is Trevi Therapeutics Inc’s upcoming earnings report date?
Trevi Therapeutics Inc’s upcoming earnings report date is Nov 07, 2024 which is in 48 days.
How were Trevi Therapeutics Inc’s earnings last quarter?
Trevi Therapeutics Inc released its earnings results on Aug 08, 2024. The company reported -$0.12 earnings per share for the quarter, missing the consensus estimate of -$0.109 by -$0.011.
Is Trevi Therapeutics Inc overvalued?
According to Wall Street analysts Trevi Therapeutics Inc’s price is currently Undervalued.
Does Trevi Therapeutics Inc pay dividends?
Trevi Therapeutics Inc does not currently pay dividends.
What is Trevi Therapeutics Inc’s EPS estimate?
Trevi Therapeutics Inc’s EPS estimate is -$0.12.
How many shares outstanding does Trevi Therapeutics Inc have?
Trevi Therapeutics Inc has 72,591,920 shares outstanding.
What happened to Trevi Therapeutics Inc’s price movement after its last earnings report?
Trevi Therapeutics Inc reported an EPS of -$0.12 in its last earnings report, missing expectations of -$0.109. Following the earnings report the stock price went up 2.143%.
Which hedge fund is a major shareholder of Trevi Therapeutics Inc?
Among the largest hedge funds holding Trevi Therapeutics Inc’s share is Viking Global Investors LP. It holds Trevi Therapeutics Inc’s shares valued at 13M.
---
Trevi Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.11 (159.54% Upside)
$9.11 (159.54% Upside)
Blogger Sentiment
Bullish
TRVI Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $337.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.5%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.01%
12-Months-Change
Fundamentals
Return on Equity
-48.09%
Trailing 12-Months
Asset Growth
-26.90%
Trailing 12-Months
Company Description
Trevi Therapeutics Inc
Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good on March 17, 2011 and is headquartered in New Haven, CT.
---
TRVI Earnings Call
Q2 2024
0:00 / 0:00
---
TRVI Stock 12 Month Forecast
Average Price Target
$9.11
▲(159.54% Upside)
Technical Analysis
Xeris Pharmaceuticals
―
EyePoint Pharmaceuticals
―
Aldeyra Therapeutics
―
KalVista Pharmaceuticals
―
Best Analysts Covering TRVI
1 Year
1 Year Success Rate
7/9 ratings generated profit
1 Year Average Return
+34.56%
reiterated a buy rating last month
Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +34.56% per trade.
---